Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Arcellx, Inc. Market Cap
The Arcellx, Inc. (ACLX) share price is expected to increase by 11.92% over the next year. This is based on calculating the average 12-month share price estimate provided by 7 stock analysts who have covered ACLX. Price targets range from $60.00 at the low end to $79.00 at the high end. The current analyst consensus for ACLX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 7 Wall Street analysts have assignedACLX 7 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Arcellx, Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ACLX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| benjamin burnett Stifel Nicolaus | Buy | $79.0 | maintained | Feb 5, 2024 |
| gil blum Needham | Buy | $71.0 | maintained | Jan 4, 2024 |
| daina graybosch Leerink Partners | Buy | $70.0 | reiterated | Dec 18, 2023 |
| george farmer Scotiabank | Buy | $66.0 | initiatedcoverage | Dec 18, 2023 |
| jason gerberry Bank of America Securities | Buy | $65.0 | maintained | Dec 12, 2023 |
| emily bodnar H.C. Wainwright | Buy | $60.0 | reiterated | Dec 12, 2023 |
| sami corwin William Blair | Buy | None | rated | Dec 12, 2023 |
| jack allen Robert W. Baird | Buy | $63.0 | reiterated | Dec 5, 2023 |
| carter gould Barclays | Buy | $62.0 | maintained | Nov 16, 2023 |
| john newman Canaccord Genuity | Buy | $66.0 | maintained | Nov 16, 2023 |
| tyler van buren TD Cowen | Buy | None | rated | Nov 13, 2023 |
| ashwani verma UBS | Buy | $52.0 | initiatedcoverage | Oct 17, 2023 |
| asthika goonewardene Truist Financial | Buy | $57.0 | maintained | Aug 14, 2023 |
| kelsey goodwin Guggenheim | Buy | None | maintained | Jun 20, 2023 |
| raju prasad William Blair | Buy | None | maintained | Dec 12, 2022 |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
When did it IPO
2022
Staff Count
98
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Rami Elghandour
Market Cap
$3.11B
In 2023, ACLX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ACLX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
INTA-USD
$41.07
FORM-USD
$40.21
MGRC-USD
$128.51
FLNC-USD
$17.01
NWL-USD
$7.67
$47.71
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
